Literature DB >> 22235075

Expert panel advocates surveillance for men with low-risk prostate cancer.

Anita Slomski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22235075     DOI： 10.1001/jama.2011.1965

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  [Prostate biopsy - an unending story].

Authors:  G Mikuz
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

2.  Medically Inappropriate or Futile Treatment: Deliberation and Justification.

Authors:  Cheryl J Misak; Douglas B White; Robert D Truog
Journal:  J Med Philos       Date:  2015-12-17

Review 3.  Enhancing active surveillance of prostate cancer: the potential of exercise medicine.

Authors:  Daniel A Galvão; Dennis R Taaffe; Nigel Spry; Robert A Gardiner; Renea Taylor; Gail P Risbridger; Mark Frydenberg; Michelle Hill; Suzanne K Chambers; Phillip Stricker; Tom Shannon; Dickon Hayne; Eva Zopf; Robert U Newton
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

4.  Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.

Authors:  Jeffrey J Tosoian; Eric JohnBull; Bruce J Trock; Patricia Landis; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Urol       Date:  2013-04-30       Impact factor: 7.450

5.  Markers of field cancerization: proposed clinical applications in prostate biopsies.

Authors:  Kristina A Trujillo; Anna C Jones; Jeffrey K Griffith; Marco Bisoffi
Journal:  Prostate Cancer       Date:  2012-05-14

6.  Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial.

Authors:  Daniel A Galvão; Dickon Hayne; Mark Frydenberg; Suzanne K Chambers; Dennis R Taaffe; Nigel Spry; Paul A Scuffham; Robert S Ware; Nicolas H Hart; Robert U Newton
Journal:  BMJ Open       Date:  2018-04-20       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.